Damora Therapeutics, Inc. SEC filings DMRA
Damora Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 20, 2026 (material agreement, change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| EFFECT | Filing | Aug 12, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| POSASR | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| S-8 POS | Filing | Aug 10, 2026 | — |
| POS AM | Filing | Aug 10, 2026 | — |
| 8-A12B/A | Filing | Aug 10, 2026 | — |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 20, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Apr 28, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
May 4, 2026 | Apr 28, 2026 |
| ARS | Annual report to shareholders | May 1, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 29, 2026 | Apr 29, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| 8-K |
Current report
Auditor change
|
Apr 20, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 23, 2026 | Mar 20, 2026 |
| S-8 | Employee stock plan registration | Mar 20, 2026 | — |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Bylaw or fiscal year change, Regulation FD disclosure
|
Mar 10, 2026 | Mar 6, 2026 |
| 8-K |
Current report
Material agreement
|
Feb 11, 2026 | Feb 10, 2026 |
| 424B5 | Prospectus supplement | Feb 11, 2026 | — |
| 424B5 | Prospectus supplement | Feb 10, 2026 | — |
| S-3ASR | Automatic shelf registration | Feb 10, 2026 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Feb 10, 2026 | Feb 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Jan 6, 2026 | Dec 31, 2025 |
| S-8 | Employee stock plan registration | Jan 2, 2026 | — |
| DEF 14A | Proxy statement | Dec 31, 2025 | Feb 9, 2026 |
| 424B3 | Prospectus | Dec 31, 2025 | — |
| EFFECT | Filing | Dec 23, 2025 | — |
| CORRESP | Letter to the SEC | Dec 22, 2025 | — |
| PRE 14A | Preliminary proxy statement | Dec 16, 2025 | Dec 16, 2025 |
| S-3 | Shelf registration | Dec 16, 2025 | — |
| 8-K/A |
Amended current report
Bylaw or fiscal year change
|
Dec 9, 2025 | Nov 10, 2025 |
| D | Filing | Nov 21, 2025 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 10, 2025 | Nov 10, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2025 | Jun 18, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| ARS | Annual report to shareholders | Apr 30, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 18, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2025 | Jun 18, 2025 |
| S-8 | Employee stock plan registration | Mar 19, 2025 | — |
| 10-K | Annual report | Mar 19, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | Nov 1, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 7, 2024 | Oct 7, 2024 |
| 8-K |
Current report
Other events
|
Sep 18, 2024 | Sep 16, 2024 |
| 8-K |
Current report
Other events
|
Sep 11, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 5, 2024 | Aug 29, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 20, 2024 |
| 10-Q | Quarterly report | Apr 29, 2024 | Mar 31, 2024 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 20, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Other events
|
Mar 26, 2024 | Mar 22, 2024 |
| S-8 | Employee stock plan registration | Mar 8, 2024 | — |
| 10-K | Annual report | Mar 8, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Dec 21, 2023 | Dec 21, 2023 |
| 10-Q | Quarterly report | Nov 6, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Other events
|
Oct 23, 2023 | Oct 23, 2023 |
| 8-K |
Current report
Listing notice
|
Oct 2, 2023 | Sep 27, 2023 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Sep 26, 2023 | Sep 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 15, 2023 | Aug 15, 2023 |
| 10-Q | Quarterly report | Jul 31, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2023 | Jun 14, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| 10-Q | Quarterly report | Apr 28, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| S-8 | Employee stock plan registration | Mar 9, 2023 | — |
| 424B5 | Prospectus supplement | Mar 9, 2023 | — |
| 10-K | Annual report | Mar 9, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 6, 2023 | Jan 6, 2023 |
| 10-Q | Quarterly report | Nov 8, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 31, 2022 | Oct 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2022 | Sep 29, 2022 |
| 10-Q | Quarterly report | Jul 29, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2022 | Jun 14, 2022 |
| 10-Q | Quarterly report | Apr 29, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Apr 28, 2022 |
| 424B5 | Prospectus supplement | Feb 18, 2022 | — |
| S-8 | Employee stock plan registration | Feb 17, 2022 | — |
| 10-K | Annual report | Feb 17, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Officer or director change
|
Feb 9, 2022 | Feb 3, 2022 |
| 8-K |
Current report
Other events
|
Jan 27, 2022 | Jan 27, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 5, 2022 | Jan 5, 2022 |
| EFFECT | Filing | Nov 12, 2021 | — |
| CORRESP | Letter to the SEC | Nov 10, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2021 | — |
| S-3 | Shelf registration | Nov 4, 2021 | — |
| 10-Q | Quarterly report | Nov 4, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 5, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2021 | May 26, 2021 |
| 10-Q | Quarterly report | May 4, 2021 | Mar 31, 2021 |
| DEFA14A | Additional proxy material | Apr 14, 2021 | — |
| DEF 14A | Proxy statement | Apr 14, 2021 | May 26, 2021 |
| S-8 | Employee stock plan registration | Mar 29, 2021 | — |
| 10-K | Annual report | Mar 29, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 15, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Officer or director change
|
Jan 8, 2021 | Jan 8, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 5, 2021 | Jan 5, 2021 |
| 10-Q | Quarterly report | Dec 11, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Officer or director change
|
Nov 23, 2020 | Nov 19, 2020 |
| D | Filing | Nov 5, 2020 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 4, 2020 | Nov 2, 2020 |
| S-8 | Employee stock plan registration | Nov 4, 2020 | — |
| 424B4 | Prospectus | Oct 30, 2020 | — |
| EFFECT | Filing | Oct 28, 2020 | — |
| CERT | 8a cert | Oct 28, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| 8-A12B | Form 8-a12b | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| S-1/A | Amended registration statement | Oct 22, 2020 | — |
| CORRESP | Letter to the SEC | Oct 20, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 7, 2020 | — |
| S-1 | Registration statement | Oct 7, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2020 | — |
| DRS | Filing | Sep 2, 2020 | — |
| D | Filing | Jan 16, 2020 | — |
Showing 135 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1800315
- Former names
- Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.